Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A prospective intervention to improve happiness and reduce burnout in oncologists.

Clemons M, Mazzarello S, Pond G, Amir E, Asmis T, Berry S, Brackstone M, Brule S, Goodwin R, Hilton JF, Julião M, Nicholas G, Stewart DJ, Wheatley-Price P, Cholmsky L, Krentel A, Hutton B, Joy AA.

Support Care Cancer. 2018 Nov 30. doi: 10.1007/s00520-018-4567-5. [Epub ahead of print]

PMID:
30506102
2.

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

Al-Baimani K, Jonker H, Zhang T, Goss GD, Laurie SA, Nicholas G, Wheatley-Price P.

Curr Oncol. 2018 Aug;25(4):e291-e297. doi: 10.3747/co.25.3978. Epub 2018 Aug 14.

3.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.

Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.

PMID:
29804902
4.

The importance of greater speed in drug development for advanced malignancies.

Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R.

Cancer Med. 2018 May;7(5):1824-1836. doi: 10.1002/cam4.1454. Epub 2018 Mar 30.

5.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
6.

Standardizing biomarker testing for Canadian patients with advanced lung cancer.

Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN.

Curr Oncol. 2018 Feb;25(1):73-82. doi: 10.3747/co.25.3867. Epub 2018 Feb 28.

7.

Regional process redesign of lung cancer care: a learning health system pilot project.

Fung-Kee-Fung M, Maziak DE, Pantarotto JR, Smylie J, Taylor L, Timlin T, Cacciotti T, Villeneuve PJ, Dennie C, Bornais C, Madore S, Aquino J, Wheatley-Price P, Ozer RS, Stewart DJ.

Curr Oncol. 2018 Feb;25(1):59-66. doi: 10.3747/co.25.3719. Epub 2018 Feb 28.

8.

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.

Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA.

Breast Cancer Res Treat. 2018 Feb;167(3):659-669. doi: 10.1007/s10549-017-4523-y. Epub 2017 Oct 22.

9.

Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes.

Dudani S, Zhu X, Yokom DW, Yamada A, Ho C, Pantarotto JR, Leighl NB, Zhang T, Wheatley-Price P.

Clin Lung Cancer. 2018 Jan;19(1):e11-e18. doi: 10.1016/j.cllc.2017.06.007. Epub 2017 Jun 21.

PMID:
28711384
10.

Physician "out of office" alert: does it work?

Clemons M, Joy AA, Hilton J, Arnaout A, Brackstone M, Wheatley-Price P, Stober C, Dinniwell R, Mazzarello S, da Costa M, Hutton B.

Curr Oncol. 2017 Jun;24(3):e176-e179. doi: 10.3747/co.24.3548. Epub 2017 Jun 27. No abstract available.

11.

The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non-small-cell Lung Cancer.

McGee SF, Zhang T, Jonker H, Laurie SA, Goss G, Nicholas G, Albaimani K, Wheatley-Price P.

Clin Lung Cancer. 2018 Jan;19(1):e91-e99. doi: 10.1016/j.cllc.2017.05.018. Epub 2017 Jun 8.

PMID:
28666762
12.

Clinician participation in CADTH's pan-Canadian Oncology Drug Review: contribution and impact on cancer drug funding recommendations.

Trudeau M, Hoskins P, Reiman T, Chambers A, Mai H, Wheatley-Price P.

Curr Oncol. 2017 Apr;24(2):71-74. doi: 10.3747/co.24.3644. Epub 2017 Apr 27. No abstract available.

13.

Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study.

Kayaniyil S, Hurry M, Wilson J, Wheatley-Price P, Melosky B, Rothenstein J, Cohen V, Koch C, Zhang J, Osenenko K, Liu G.

Curr Oncol. 2016 Dec;23(6):e589-e597. doi: 10.3747/co.23.3273. Epub 2016 Dec 21.

14.

Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy.

Valdes M, Nicholas G, Goss GD, Wheatley-Price P.

Curr Oncol. 2016 Dec;23(6):386-390. doi: 10.3747/co.23.3191. Epub 2016 Dec 21.

15.

A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.

Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA.

J Thorac Oncol. 2016 Nov;11(11):2018-2021. doi: 10.1016/j.jtho.2016.06.024. Epub 2016 Jul 20.

16.

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D.

Pancreatology. 2016 Nov - Dec;16(6):1106-1112. doi: 10.1016/j.pan.2016.08.013. Epub 2016 Aug 30.

PMID:
27600995
17.

Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older.

Lai P, Sud S, Zhang T, Asmis T, Wheatley-Price P.

Curr Oncol. 2016 Jun;23(3):144-53. doi: 10.3747/co.23.2996. Epub 2016 Jun 9.

18.

Treatment of Lung Cancer in Medically Compromised Patients.

Crawford J, Wheatley-Price P, Feliciano JL.

Am Soc Clin Oncol Educ Book. 2016;35:e484-91. doi: 10.14694/EDBK_158713.

19.

Current and Evolving Methods to Visualize Biological Data in Cancer Research.

Chia PL, Gedye C, Boutros PC, Wheatley-Price P, John T.

J Natl Cancer Inst. 2016 May 31;108(8). pii: djw031. doi: 10.1093/jnci/djw031. Print 2016 Aug. Review.

20.

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

Brule SY, Al-Baimani K, Jonker H, Zhang T, Nicholas G, Goss G, Laurie SA, Wheatley-Price P.

Lung Cancer. 2016 Jul;97:15-21. doi: 10.1016/j.lungcan.2016.04.007. Epub 2016 Apr 14. Review.

PMID:
27237022
21.

Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.

Dudani S, Leighl NB, Ho C, Pantarotto JR, Zhu X, Zhang T, Wheatley-Price P.

Lung Cancer. 2016 Apr;94:74-80. doi: 10.1016/j.lungcan.2016.02.002. Epub 2016 Feb 3.

PMID:
26973210
22.

Patients With Advanced Non-Small Cell Lung Cancer Requiring Inpatient Medical Oncology Consultation: Characteristics, Referral Patterns, and Outcomes.

Gotfrit J, Zhang T, Zanon-Heacock S, Wheatley-Price P.

Clin Lung Cancer. 2016 Jul;17(4):292-300. doi: 10.1016/j.cllc.2015.12.011. Epub 2015 Dec 30.

PMID:
26837473
23.

Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G.

JAMA Oncol. 2016 Feb;2(2):225-31. doi: 10.1001/jamaoncol.2015.3730.

PMID:
26562292
24.

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.

Saint-Pierre MD, Pease C, Mithoowani H, Zhang T, Nicholas GA, Laurie SA, Wheatley-Price P.

Lung Cancer Int. 2015;2015:590148. doi: 10.1155/2015/590148. Epub 2015 Mar 2.

25.

Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and older.

Sud S, Lai P, Zhang T, Clemons M, Wheatley-Price P.

J Geriatr Oncol. 2015 Sep;6(5):395-400. doi: 10.1016/j.jgo.2015.07.002. Epub 2015 Aug 13.

PMID:
26278886
26.

The incidence and clinical impact of bone metastases in non-small cell lung cancer.

Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley-Price P.

Lung Cancer. 2015 Aug;89(2):197-202. doi: 10.1016/j.lungcan.2015.04.007. Epub 2015 May 11.

PMID:
26003503
27.

The role of palliative chemotherapy in hospitalized patients.

Wheatley-Price P, Ali M, Balchin K, Spencer J, Fitzgibbon E, Cripps C.

Curr Oncol. 2014 Aug;21(4):187-92. doi: 10.3747/co.21.1989.

28.

Thymic epithelial neoplasms: a 12-year Canadian regional cancer program experience.

Wheatley-Price P, Jonker H, Jonker D, Shamji F, Gomes MM.

Clin Lung Cancer. 2014 May;15(3):231-6. doi: 10.1016/j.cllc.2013.12.003. Epub 2013 Dec 27.

PMID:
24485232
29.

Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

Russell K, Healy B, Pantarotto J, Laurie SA, MacRae R, Sabri E, Wheatley-Price P.

Clin Lung Cancer. 2014 May;15(3):237-43. doi: 10.1016/j.cllc.2013.12.007. Epub 2013 Dec 27.

PMID:
24461300
30.

Third-line chemotherapy in small-cell lung cancer: an international analysis.

Simos D, Sajjady G, Sergi M, Liew MS, Califano R, Ho C, Leighl N, White S, Summers Y, Petrcich W, Wheatley-Price P.

Clin Lung Cancer. 2014 Mar;15(2):110-8. doi: 10.1016/j.cllc.2013.11.003. Epub 2013 Nov 14.

PMID:
24365050
31.

The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.

Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, Dent S.

Breast Cancer Res Treat. 2013 Aug;141(1):111-7. doi: 10.1007/s10549-013-2659-y. Epub 2013 Aug 14.

PMID:
23942873
32.

Incidence and consequences of bone metastases in lung cancer patients.

Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P.

J Bone Oncol. 2013 Jan 17;2(1):22-9. doi: 10.1016/j.jbo.2012.12.004. eCollection 2013 Feb.

33.

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M.

Curr Oncol. 2012 Dec;19(6):e414-21. doi: 10.3747/co.19.1074.

34.

Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma.

Sulpher JA, Owen SP, Hon H, Tobros K, Shepherd FA, Sabri E, Gomes M, Sekhon H, Liu G, Canil CM, Wheatley-Price P.

Clin Lung Cancer. 2013 May;14(3):238-44. doi: 10.1016/j.cllc.2012.11.004. Epub 2013 Jan 4. Review.

PMID:
23291255
35.

Holiday reading: The Mayan Doomsday's effect on survival outcomes in clinical trials.

Wheatley-Price P, Hutton B, Clemons M.

CMAJ. 2012 Dec 11;184(18):2021-2. doi: 10.1503/cmaj.121616. No abstract available.

36.

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M.

J Support Oncol. 2013 Mar;11(1):14-21.

PMID:
22763232
37.

Pharmacogenetic and germline prognostic markers of lung cancer.

Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, Wheatley-Price P, Hung RJ, Shepherd FA, Liu G.

J Thorac Oncol. 2011 Feb;6(2):296-304. doi: 10.1097/JTO.0b013e3181ffe909.

38.

Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G.

J Clin Oncol. 2010 Jul 10;28(20):3316-22. doi: 10.1200/JCO.2009.26.9944. Epub 2010 May 24.

PMID:
20498407
39.

The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.

Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA; NCIC Clinical Trials Group.

J Thorac Oncol. 2010 May;5(5):640-8. doi: 10.1097/JTO.0b013e3181d40a1b.

40.

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.

Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R, Danson S, Lorigan P, Thatcher N, Shepherd FA.

Ann Oncol. 2010 Oct;21(10):2023-8. doi: 10.1093/annonc/mdq067. Epub 2010 Mar 23.

PMID:
20332134
41.

The influence of sex in non-small cell lung cancer.

Wheatley-Price P, Blackhall F, Thatcher N.

Onkologie. 2009 Oct;32(10):547-8. doi: 10.1159/000235609. Epub 2009 Sep 21. No abstract available.

42.

The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, Lorigan P, Thatcher N, Blackhall FH, Shepherd FA.

Ann Oncol. 2010 Feb;21(2):232-7. doi: 10.1093/annonc/mdp300. Epub 2009 Aug 12.

PMID:
19675093
43.

Resident preparedness in discussing prognosis in patients with advanced lung cancer.

Wheatley-Price P, Massey C, Panzarella T, Shepherd FA, Mikhael J.

Support Care Cancer. 2010 Apr;18(4):491-7. doi: 10.1007/s00520-009-0702-7. Epub 2009 Jul 21.

PMID:
19629536
44.

Prevention and management of bone metastases in lung cancer: a review.

Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA.

J Thorac Oncol. 2009 Feb;4(2):251-9. doi: 10.1097/JTO.0b013e31819518fc. Review.

45.

Targeting angiogenesis in the treatment of lung cancer.

Wheatley-Price P, Shepherd FA.

J Thorac Oncol. 2008 Oct;3(10):1173-84. doi: 10.1097/JTO.0b013e318187220f. Review.

46.

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA.

J Clin Oncol. 2008 May 10;26(14):2350-7. doi: 10.1200/JCO.2007.15.2280.

PMID:
18467727
47.

Genetic polymorphisms and head and neck cancer outcomes: a review.

Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price P, Waldron J, Goldstein D, Meyer F, Bairati I, Liu G.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):490-9. doi: 10.1158/1055-9965.EPI-07-2714. Review.

48.

Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.

Wheatley-Price P, Shepherd FA.

Curr Opin Oncol. 2008 Mar;20(2):162-75. doi: 10.1097/CCO.0b013e3282f335a3. Review.

PMID:
18300766
49.

Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma.

Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, Liu G.

Cancer. 2008 Mar 1;112(5):1037-42. doi: 10.1002/cncr.23267.

50.

Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.

Liu G, Wheatley-Price P, Zhou W, Park S, Heist RS, Asomaning K, Wain JC, Lynch TJ, Su L, Christiani DC.

Int J Cancer. 2008 Feb 15;122(4):915-8.

Supplemental Content

Loading ...
Support Center